Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
David Mountcastle, the Executive Vice President and Chief Financial Officer of Privia Health Group , Inc. (NASDAQ:PRVA), recently sold 5,630 shares of the company’s common stock. The shares were sold at an average price of $22.38, amounting to a total transaction value of $125,999. The transaction comes as the $2.66 billion healthcare company trades near InvestingPro’s Fair Value estimate, with the stock having gained nearly 29% over the past six months.
Following this transaction, Mountcastle retains direct ownership of 179,676 shares. Additionally, an indirect holding of 8,695 shares is maintained by his spouse. The sale was conducted as part of a "sell to cover" transaction to meet tax withholding obligations related to the vesting and settlement of restricted stock units. InvestingPro analysis shows the company maintains a strong financial health score of GREAT, with net income expected to grow this year. Subscribers can access 8 additional ProTips and comprehensive insider trading analysis in the Pro Research Report.
In other recent news, Privia Health Group has announced significant changes to its executive compensation structure. The company’s board decided to amend the employment terms for Parth Mehrotra, who will now receive an annual base salary of $650,000 starting March 24, 2025, along with an annual performance bonus of up to 125% of his base salary and a long-term incentive award valued at $8,000,000. Analysts from Jefferies, Canaccord Genuity, JMP Securities, and Piper Sandler have all raised their price targets for Privia Health, reflecting confidence in the company’s future performance. Jefferies increased its price target to $29, citing the company’s strong cash generation and minimal exposure to regulatory uncertainty. Canaccord Genuity raised its target to $30, highlighting Privia’s consistent performance and prudent business approach. JMP Securities set a new target of $29, acknowledging the company’s solid guidance for 2025 and its diversified platform. Piper Sandler notably raised its price target to $40, emphasizing Privia Health’s strategic approach to value-based care and stable growth. These updates collectively underscore the positive outlook analysts have for Privia Health’s financial health and strategic positioning in the healthcare market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.